Background
Cristina Adriana Popa
A dose of CONFIDENCE: Building evidence for ...

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Background
swapnil hiremath
From single shots to strategy: How CAPTIVATE is ...

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Background
Cristina Adriana Popa
Are E-Nudges Enough to Push Guideline-Based CKD ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

Are E-Nudges Enough to Push Guideline-Based CKD Therapy?
Background
Brian Rifkin
STAMP of Approval: Tacrolimus vs MMF in ...

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance

Background

Creatinine to Cystatin C: Time to Change?

Creatinine to Cystatin C: Time to Change?

This week, we will discuss a paper from Nature Medicine. Cystatin C has been around for a while, but not taken off in routine practice. Is it time for it to do so? In this study, authors from Glasgow using the UKBiobank data show that cystatin C improves the prediction of bad outcomes.

Can difelikefalin scratch uremic pruritus?

Can difelikefalin scratch uremic pruritus?

This week we will be discussing the KALM-1 trial which was presented at the Late Breaking and High Impact Trial Session at the recently completed #KidneyWk. It was simultaneously published in the NEJM. Kalm-1 investigated whether difelikefalin, a opioid kappa agonist, decreased uremic pruritus.

Patiromer, spironolactone and resistant hypertension.

Patiromer, spironolactone and resistant hypertension.

The new generation of potassium binders bind potassium but can they improve patient outcomes? These second order questions are starting to be answered. Join us this week to discuss the use of patiromer and spironolactone in patients with resistant hypertension.The AMBER Study

Can We Stop MUC-1 From Mucking Up the Kidney

Can We Stop MUC-1 From Mucking Up the Kidney

Some cases of ADTKD are due to mutations of the MUC-1 gene, one mutation is a frame shift mutation that results in a premature stop codon. which results in accumulation of the abnormally short, and toxic protein MUC-1 fs . The researchers found a small protein, BRD4780, that reroute MUC-1fs to lysosomes, preventing proteinopathy and possibly altering the natural history of the disease.